Last 12 months
Inside the activity.
0 purchase rows · 59 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 9 |
| Jan 2026 | 0 | 4 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 26 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 6 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 14 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 15, 2024 Filed Mar 19, 2024 23:04 UTC |
Whitfield Dianne C.Chief Human Resources Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 7,248 | $0.00 | $0.00 |
DisclosureSEC source: 0001819790-24-000044 · wk-form4_1710889444.xml · derivative · entry 4 Whitfield Dianne C. · CIK 0001839516 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,745 Underlying: Common Stock · 7,248 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: RSUs granted on March 8, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. The RSUs will vest in equal installments on March 15, 2024, March 15, 2025, March 15, 2026 and March 15, 2027, subject to the Reporting Person's continuous service. F5 · derivative.expiration_date: RSUs granted on March 8, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. The RSUs will vest in equal installments on March 15, 2024, March 15, 2025, March 15, 2026 and March 15, 2027, subject to the Reporting Person's continuous service. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 23:04 UTC |
Whitfield Dianne C.Chief Human Resources Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 4,463 | $0.00 | $0.00 |
DisclosureSEC source: 0001819790-24-000044 · wk-form4_1710889444.xml · derivative · entry 3 Whitfield Dianne C. · CIK 0001839516 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,925 Underlying: Common Stock · 4,463 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: RSUs granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. The RSUs will vest in equal installments on March 15, 2023, March 15, 2024, March 15, 2025 and March 15, 2026, subject to the Reporting Person's continuous service. F4 · derivative.expiration_date: RSUs granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. The RSUs will vest in equal installments on March 15, 2023, March 15, 2024, March 15, 2025 and March 15, 2026, subject to the Reporting Person's continuous service. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 23:04 UTC |
Whitfield Dianne C.Chief Human Resources Officer
|
Exercise / conversionCommon Stock | 11,711 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001819790-24-000044 · wk-form4_1710889444.xml · nonDerivative · entry 1 Whitfield Dianne C. · CIK 0001839516 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,495 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 23:03 UTC |
Neervannan SeshadriChief Operating Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 8,148 | $0.00 | $0.00 |
DisclosureSEC source: 0001819790-24-000043 · wk-form4_1710889381.xml · derivative · entry 4 Neervannan Seshadri · CIK 0001827584 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,444 Underlying: Common Stock · 8,148 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F6 · derivative.exercise_date: RSUs granted on March 8, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service. F6 · derivative.expiration_date: RSUs granted on March 8, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 23:03 UTC |
Neervannan SeshadriChief Operating Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 5,097 | $0.00 | $0.00 |
DisclosureSEC source: 0001819790-24-000043 · wk-form4_1710889381.xml · derivative · entry 3 Neervannan Seshadri · CIK 0001827584 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,194 Underlying: Common Stock · 5,097 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: RSUs granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service. F5 · derivative.expiration_date: RSUs granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 23:03 UTC |
Neervannan SeshadriChief Operating Officer
|
Exercise / conversionCommon Stock | 13,245 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001819790-24-000043 · wk-form4_1710889381.xml · nonDerivative · entry 1 Neervannan Seshadri · CIK 0001827584 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,646 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). F2 · balance_after: Includes 1,705 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2023. Read SEC document |
| March 07, 2024 Filed Mar 11, 2024 21:57 UTC |
Azamian Bobak R.Director · President/CEO and Board Chair
|
GrantRestricted Stock Units · Derivative | 92,485 | $0.00 | $0.00 |
DisclosureSEC source: 0001819790-24-000037 · wk-form4_1710194265.xml · derivative · entry 2 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,485 Underlying: Common Stock · 92,485 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027, and 2028, subject to the Reporting Person's continuous service. F3 · derivative.expiration_date: 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027, and 2028, subject to the Reporting Person's continuous service. Read SEC document |
| March 07, 2024 Filed Mar 11, 2024 21:57 UTC |
Azamian Bobak R.Director · President/CEO and Board Chair
|
GrantStock Option (right to buy) · Derivative | 136,947 | $0.00 Strike: $35.50 | $0.00 |
DisclosureSEC source: 0001819790-24-000037 · wk-form4_1710194265.xml · derivative · entry 1 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 136,947 Underlying: Common Stock · 136,947 shares Expires 2034-03-06 F1 · derivative.exercise_date: 25% of the option shares shall vest on March 7, 2025, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years subject to the Reporting Person's continuous service. Read SEC document |
| March 07, 2024 Filed Mar 11, 2024 21:45 UTC |
Wahl BryanGeneral Counsel
|
GrantRestricted Stock Units · Derivative | 28,702 | $0.00 | $0.00 |
DisclosureSEC source: 0001841401-24-000001 · wk-form4_1710193510.xml · derivative · entry 2 Wahl Bryan · CIK 0001841401 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,702 Underlying: Common Stock · 28,702 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027, and 2028, subject to the Reporting Person's continuous service. F3 · derivative.expiration_date: 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027, and 2028, subject to the Reporting Person's continuous service. Read SEC document |
| March 07, 2024 Filed Mar 11, 2024 21:45 UTC |
Wahl BryanGeneral Counsel
|
GrantStock Option (right to buy) · Derivative | 42,500 | $0.00 Strike: $35.50 | $0.00 |
DisclosureSEC source: 0001841401-24-000001 · wk-form4_1710193510.xml · derivative · entry 1 Wahl Bryan · CIK 0001841401 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,500 Underlying: Common Stock · 42,500 shares Expires 2034-03-06 F1 · derivative.exercise_date: 25% of the option shares shall vest on March 7, 2025, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years subject to the Reporting Person's continuous service. Read SEC document |
| March 07, 2024 Filed Mar 11, 2024 21:12 UTC |
Mottiwala AzizChief Commercial Officer
|
GrantRestricted Stock Units · Derivative | 32,079 | $0.00 | $0.00 |
DisclosureSEC source: 0001819790-24-000034 · wk-form4_1710191542.xml · derivative · entry 2 Mottiwala Aziz · CIK 0001788542 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,079 Underlying: Common Stock · 32,079 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027, and 2028, subject to the Reporting Person's continuous service. F3 · derivative.expiration_date: 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027, and 2028, subject to the Reporting Person's continuous service. Read SEC document |
| March 07, 2024 Filed Mar 11, 2024 21:12 UTC |
Mottiwala AzizChief Commercial Officer
|
GrantStock Option (right to buy) · Derivative | 47,500 | $0.00 Strike: $35.50 | $0.00 |
DisclosureSEC source: 0001819790-24-000034 · wk-form4_1710191542.xml · derivative · entry 1 Mottiwala Aziz · CIK 0001788542 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,500 Underlying: Common Stock · 47,500 shares Expires 2034-03-06 F1 · derivative.exercise_date: 25% of the option shares shall vest on March 7, 2025, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years subject to the Reporting Person's continuous service. Read SEC document |
| March 07, 2024 Filed Mar 11, 2024 21:12 UTC |
Whitfield Dianne C.Chief Human Resources Officer
|
GrantRestricted Stock Units · Derivative | 28,702 | $0.00 | $0.00 |
DisclosureSEC source: 0001819790-24-000033 · wk-form4_1710191517.xml · derivative · entry 2 Whitfield Dianne C. · CIK 0001839516 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,702 Underlying: Common Stock · 28,702 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027, and 2028, subject to the Reporting Person's continuous service. F3 · derivative.expiration_date: 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027, and 2028, subject to the Reporting Person's continuous service. Read SEC document |
| March 07, 2024 Filed Mar 11, 2024 21:12 UTC |
Whitfield Dianne C.Chief Human Resources Officer
|
GrantStock Option (right to buy) · Derivative | 42,500 | $0.00 Strike: $35.50 | $0.00 |
DisclosureSEC source: 0001819790-24-000033 · wk-form4_1710191517.xml · derivative · entry 1 Whitfield Dianne C. · CIK 0001839516 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,500 Underlying: Common Stock · 42,500 shares Expires 2034-03-06 F1 · derivative.exercise_date: 25% of the option shares shall vest on March 7, 2025, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years subject to the Reporting Person's continuous service. Read SEC document |
| March 07, 2024 Filed Mar 11, 2024 21:11 UTC |
Farrow Jeffrey SSee Remarks
|
GrantRestricted Stock Units · Derivative | 32,079 | $0.00 | $0.00 |
DisclosureSEC source: 0001819790-24-000032 · wk-form4_1710191483.xml · derivative · entry 2 Farrow Jeffrey S · CIK 0001405253 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,079 Underlying: Common Stock · 32,079 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027, and 2028, subject to the Reporting Person's continuous service. F3 · derivative.expiration_date: 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027, and 2028, subject to the Reporting Person's continuous service. Read SEC document |
| March 07, 2024 Filed Mar 11, 2024 21:11 UTC |
Farrow Jeffrey SSee Remarks
|
GrantStock Option (right to buy) · Derivative | 47,500 | $0.00 Strike: $35.50 | $0.00 |
DisclosureSEC source: 0001819790-24-000032 · wk-form4_1710191483.xml · derivative · entry 1 Farrow Jeffrey S · CIK 0001405253 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,500 Underlying: Common Stock · 47,500 shares Expires 2034-03-06 F1 · derivative.exercise_date: 25% of the option shares shall vest on March 7, 2025, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years subject to the Reporting Person's continuous service. Read SEC document |
| March 07, 2024 Filed Mar 11, 2024 21:10 UTC |
Neervannan SeshadriChief Operating Officer
|
GrantRestricted Stock Units · Derivative | 32,079 | $0.00 | $0.00 |
DisclosureSEC source: 0001819790-24-000031 · wk-form4_1710191431.xml · derivative · entry 2 Neervannan Seshadri · CIK 0001827584 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,079 Underlying: Common Stock · 32,079 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027, and 2028, subject to the Reporting Person's continuous service. F3 · derivative.expiration_date: 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027, and 2028, subject to the Reporting Person's continuous service. Read SEC document |
| March 07, 2024 Filed Mar 11, 2024 21:10 UTC |
Neervannan SeshadriChief Operating Officer
|
GrantStock Option (right to buy) · Derivative | 47,500 | $0.00 Strike: $35.50 | $0.00 |
DisclosureSEC source: 0001819790-24-000031 · wk-form4_1710191431.xml · derivative · entry 1 Neervannan Seshadri · CIK 0001827584 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,500 Underlying: Common Stock · 47,500 shares Expires 2034-03-06 F1 · derivative.exercise_date: 25% of the option shares shall vest on March 7, 2025, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years subject to the Reporting Person's continuous service. Read SEC document |
| January 25, 2024 Filed Jan 30, 2024 21:31 UTC |
Lin Elizabeth YeuDirector
|
GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $26.25 | $0.00 |
DisclosureSEC source: 0001819790-24-000008 · wk-form4_1706650295.xml · derivative · entry 1 Lin Elizabeth Yeu · CIK 0001842190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2034-01-24 F1 · derivative.exercise_date: Option granted in connection with certain consulting services being provided by the Reporting Person. The option will vest in full on January 30, 2025, subject to the Reporting Person's continuous service through such date. Read SEC document |
| December 27, 2023 Filed Dec 29, 2023 22:08 UTC |
Azamian Bobak R.Director · President/CEO and Board Chair
|
SaleCommon Stock | 8,000 | $20.22 | $161,760.00 |
DisclosureSEC source: 0001827672-23-000050 · wk-form4_1703887719.xml · nonDerivative · entry 1 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: Plan reported Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 830,106 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 23, 2023. F2 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $20.00 to $20.43. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| December 20, 2023 Filed Dec 22, 2023 22:32 UTC |
Trevejo Jose M.CHIEF MEDICAL OFFICER
|
SaleCommon Stock | 2,252 | $20.00 | $45,040.00 |
DisclosureSEC source: 0001661539-23-000008 · wk-form4_1703284363.xml · nonDerivative · entry 1 Trevejo Jose M. · CIK 0001661539 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,251 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2023. Read SEC document |
| December 20, 2023 Filed Dec 22, 2023 22:30 UTC |
Azamian Bobak R.Director · President/CEO and Board Chair
|
SaleCommon Stock | 30,557 | $20.36 | $622,140.52 |
DisclosureSEC source: 0001827672-23-000048 · wk-form4_1703284219.xml · nonDerivative · entry 2 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: Plan reported Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 838,106 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 23, 2023. F4 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $20.10 to $20.73. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| December 20, 2023 Filed Dec 22, 2023 22:30 UTC |
Azamian Bobak R.Director · President/CEO and Board Chair
|
SaleCommon Stock | 9,443 | $19.96 | $188,482.28 |
DisclosureSEC source: 0001827672-23-000048 · wk-form4_1703284219.xml · nonDerivative · entry 1 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: Plan reported Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 868,663 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 23, 2023. F2 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $19.09 to $20.08. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| December 15, 2023 Filed Dec 19, 2023 23:30 UTC |
Goldberg Andrew D.Director
|
PurchaseCommon Stock | 1,000 | $18.96 | $18,960.00 |
DisclosureSEC source: 0001827722-23-000002 · wk-form4_1703028650.xml · nonDerivative · entry 1 Goldberg Andrew D. · CIK 0001827722 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,000 Read SEC document |
| December 02, 2023 Filed Dec 5, 2023 23:27 UTC |
YARNO WENDY LDirector
|
Exercise / conversionRestricted Stock Units · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001819790-23-000085 · wk-form4_1701818857.xml · derivative · entry 2 YARNO WENDY L · CIK 0001181186 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Company's common stock. F3 · derivative.exercise_date: RSUs granted in connection with the Reporting Person's service as the Lead Independent Director. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. F3 · derivative.expiration_date: RSUs granted in connection with the Reporting Person's service as the Lead Independent Director. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. Read SEC document |
| December 02, 2023 Filed Dec 5, 2023 23:27 UTC |
YARNO WENDY LDirector
|
Exercise / conversionCommon Stock | 5,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001819790-23-000085 · wk-form4_1701818857.xml · nonDerivative · entry 1 YARNO WENDY L · CIK 0001181186 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. F1 · price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. Read SEC document |
| November 30, 2023 Filed Dec 1, 2023 21:58 UTC |
Whitfield Dianne C.Chief Human Resources Officer
|
SaleCommon Stock | 8,355 | $16.31 | $136,270.05 |
DisclosureSEC source: 0001839516-23-000006 · wk-form4_1701467883.xml · nonDerivative · entry 2 Whitfield Dianne C. · CIK 0001839516 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,784 F2 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| November 30, 2023 Filed Dec 1, 2023 21:55 UTC |
Wahl BryanGeneral Counsel
|
SaleCommon Stock | 8,356 | $16.31 | $136,286.36 |
DisclosureSEC source: 0001841401-23-000007 · wk-form4_1701467742.xml · nonDerivative · entry 2 Wahl Bryan · CIK 0001841401 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,966 F2 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| November 29, 2023 Filed Dec 1, 2023 21:58 UTC |
Whitfield Dianne C.Chief Human Resources Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 23,920 | $0.00 | $0.00 |
DisclosureSEC source: 0001839516-23-000006 · wk-form4_1701467883.xml · derivative · entry 3 Whitfield Dianne C. · CIK 0001839516 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,920 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: RSUs granted under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 30% of the RSUs vested on November 29, 2022, and 70% on November 29, 2023, subject to the Reporting Person's continuous service. F3 · derivative.exercise_date: RSUs granted under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 30% of the RSUs vested on November 29, 2022, and 70% on November 29, 2023, subject to the Reporting Person's continuous service. F3 · derivative.expiration_date: RSUs granted under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 30% of the RSUs vested on November 29, 2022, and 70% on November 29, 2023, subject to the Reporting Person's continuous service. Read SEC document |
| November 29, 2023 Filed Dec 1, 2023 21:58 UTC |
Whitfield Dianne C.Chief Human Resources Officer
|
Exercise / conversionCommon Stock | 23,920 | $0.00 | $0.00 |
DisclosureSEC source: 0001839516-23-000006 · wk-form4_1701467883.xml · nonDerivative · entry 1 Whitfield Dianne C. · CIK 0001839516 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,139 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The Reporting Person received restricted stock units ("RSUs") which represent a contingent right to receive one share of Issuer's Common Stock for each RSU. This reported transaction represents the settlement of RSUs vested as of November 29, 2023. Read SEC document |
| November 29, 2023 Filed Dec 1, 2023 21:55 UTC |
Wahl BryanGeneral Counsel
|
Exercise / conversionRestricted Stock Units · Derivative | 23,920 | $0.00 | $0.00 |
DisclosureSEC source: 0001841401-23-000007 · wk-form4_1701467742.xml · derivative · entry 3 Wahl Bryan · CIK 0001841401 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,920 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: RSUs granted under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 30% of the RSUs vested on November 29, 2022, and 70% on November 29, 2023, subject to the Reporting Person's continuous service. F3 · derivative.exercise_date: RSUs granted under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 30% of the RSUs vested on November 29, 2022, and 70% on November 29, 2023, subject to the Reporting Person's continuous service. F3 · derivative.expiration_date: RSUs granted under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 30% of the RSUs vested on November 29, 2022, and 70% on November 29, 2023, subject to the Reporting Person's continuous service. Read SEC document |
| November 29, 2023 Filed Dec 1, 2023 21:55 UTC |
Wahl BryanGeneral Counsel
|
Exercise / conversionCommon Stock | 23,920 | $0.00 | $0.00 |
DisclosureSEC source: 0001841401-23-000007 · wk-form4_1701467742.xml · nonDerivative · entry 1 Wahl Bryan · CIK 0001841401 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,322 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The Reporting Person received restricted stock units ("RSUs") which represent a contingent right to receive one share of Issuer's Common Stock for each RSU. This reported transaction represents the settlement of RSUs vested as of November 29, 2023. Read SEC document |
| November 15, 2023 Filed Nov 17, 2023 21:50 UTC |
Azamian Bobak R.Director · President/CEO and Board Chair
|
SaleCommon Stock | 200 | $19.28 | $3,856.00 |
DisclosureSEC source: 0001827672-23-000045 · wk-form4_1700257834.xml · nonDerivative · entry 3 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: Plan reported Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 878,106 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 23, 2023. F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| November 15, 2023 Filed Nov 17, 2023 21:50 UTC |
Azamian Bobak R.Director · President/CEO and Board Chair
|
SaleCommon Stock | 4,904 | $18.54 | $90,920.16 |
DisclosureSEC source: 0001827672-23-000045 · wk-form4_1700257834.xml · nonDerivative · entry 2 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: Plan reported Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 878,306 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 23, 2023. F4 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $18.27 to $19.21. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| November 15, 2023 Filed Nov 17, 2023 21:50 UTC |
Azamian Bobak R.Director · President/CEO and Board Chair
|
SaleCommon Stock | 2,896 | $18.01 | $52,156.96 |
DisclosureSEC source: 0001827672-23-000045 · wk-form4_1700257834.xml · nonDerivative · entry 1 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: Plan reported Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 883,210 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 23, 2023. F2 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $17.25 to $18.14. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| October 18, 2023 Filed Oct 20, 2023 20:41 UTC |
Azamian Bobak R.Director · President/CEO and Board Chair
|
SaleCommon Stock | 8,000 | $13.24 | $105,920.00 |
DisclosureSEC source: 0001827672-23-000043 · wk-form4_1697834436.xml · nonDerivative · entry 1 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: Plan reported Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 886,106 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 23, 2023. F2 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $13.00 to $13.65. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| October 05, 2023 Filed Oct 6, 2023 21:21 UTC |
Trevejo Jose M.CHIEF MEDICAL OFFICER
|
SaleCommon Stock | 1,604 | $18.00 | $28,872.00 |
DisclosureSEC source: 0001661539-23-000006 · wk-form4_1696627288.xml · nonDerivative · entry 1 Trevejo Jose M. · CIK 0001661539 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,503 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2023. Read SEC document |
| September 20, 2023 Filed Sep 22, 2023 21:30 UTC |
Azamian Bobak R.Director · President/CEO and Board Chair
|
SaleCommon Stock | 8,000 | $17.21 | $137,680.00 |
DisclosureSEC source: 0001827672-23-000041 · wk-form4_1695418206.xml · nonDerivative · entry 1 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: Plan reported Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 894,106 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 23, 2023. F2 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $16.74 to $17.67. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| September 15, 2023 Filed Sep 19, 2023 20:25 UTC |
Morrison Scott WDirector
|
Exercise / conversionRestricted Stock Units · Derivative | 1,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001819790-23-000075 · wk-form4_1695155145.xml · derivative · entry 2 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,667 Underlying: Common Stock · 1,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. F2 · derivative.exercise_date: The RSUs vest in three equal annual installments on September 15th of 2023, 2024, and 2025, subject to the Reporting Person's continuous service. F2 · derivative.expiration_date: The RSUs vest in three equal annual installments on September 15th of 2023, 2024, and 2025, subject to the Reporting Person's continuous service. Read SEC document |
| September 15, 2023 Filed Sep 19, 2023 20:25 UTC |
Morrison Scott WDirector
|
Exercise / conversionCommon Stock | 1,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001819790-23-000075 · wk-form4_1695155145.xml · nonDerivative · entry 1 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. F1 · price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. Read SEC document |
| August 23, 2023 Filed Aug 25, 2023 21:12 UTC |
Azamian Bobak R.Director · President/CEO and Board Chair
|
SaleCommon Stock | 8,000 | $17.23 | $137,840.00 |
DisclosureSEC source: 0001827672-23-000039 · wk-form4_1692997962.xml · nonDerivative · entry 1 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: Plan reported Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 902,106 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 23, 2023. F2 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $17.00 to $17.42. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| August 15, 2023 Filed Aug 17, 2023 22:02 UTC |
Lin Elizabeth YeuDirector
|
PurchaseCommon Stock | 9,506 | $16.80 | $159,700.80 |
DisclosureSEC source: 0001819790-23-000073 · wk-form4_1692309770.xml · nonDerivative · entry 1 Lin Elizabeth Yeu · CIK 0001842190 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse's Roth IRA Disclosed balance after: 15,866 Read SEC document |
| July 19, 2023 Filed Jul 21, 2023 21:46 UTC |
Mottiwala AzizChief Commercial Officer
|
SaleCommon Stock | 2,400 | $20.05 | $48,120.00 |
DisclosureSEC source: 0001788542-23-000006 · wk-form4_1689976000.xml · nonDerivative · entry 1 Mottiwala Aziz · CIK 0001788542 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,806 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 26, 2022. F2 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $20.00 to $20.10. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes 120 shares acquired under the Issuer's employee stock purchase plan on June 30, 2023. Read SEC document |
| July 19, 2023 Filed Jul 21, 2023 21:42 UTC |
Azamian Bobak R.Director · President/CEO and Board Chair
|
SaleCommon Stock | 99,726 | $20.04 | $1,998,509.04 |
DisclosureSEC source: 0001827672-23-000037 · wk-form4_1689975765.xml · nonDerivative · entry 2 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: Plan reported Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 910,106 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2022 F4 · shares: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $19.73 to $20.12. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| July 19, 2023 Filed Jul 21, 2023 21:42 UTC |
Azamian Bobak R.Director · President/CEO and Board Chair
|
SaleCommon Stock | 4,174 | $19.28 | $80,474.72 |
DisclosureSEC source: 0001827672-23-000037 · wk-form4_1689975765.xml · nonDerivative · entry 1 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: Plan reported Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 1,009,832 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2022 F2 · shares: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $18.69 to $19.66. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| July 12, 2023 Filed Jul 14, 2023 20:40 UTC |
Azamian Bobak R.Director · President/CEO and Board Chair
|
SaleCommon Stock | 9,000 | $17.35 | $156,150.00 |
DisclosureSEC source: 0001827672-23-000035 · wk-form4_1689367221.xml · nonDerivative · entry 1 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: Plan reported Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 1,014,006 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2022. F2 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $17.24 to $17.69. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| June 22, 2023 Filed Jun 26, 2023 22:10 UTC |
Crane Rosemary ADirector
|
GrantRestricted Stock Units · Derivative | 3,350 | $0.00 | $0.00 |
DisclosureSEC source: 0001819790-23-000062 · wk-form4_1687817414.xml · derivative · entry 2 Crane Rosemary A · CIK 0001443343 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,350 Underlying: Common Stock · 3,350 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock. F3 · derivative.exercise_date: RSUs granted on June 22, 2023, in connection with the Reporting Person's service as a non-employee director as of the Company's 2023 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. F3 · derivative.expiration_date: RSUs granted on June 22, 2023, in connection with the Reporting Person's service as a non-employee director as of the Company's 2023 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. Read SEC document |
| June 22, 2023 Filed Jun 26, 2023 22:10 UTC |
Crane Rosemary ADirector
|
GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $17.99 | $0.00 |
DisclosureSEC source: 0001819790-23-000062 · wk-form4_1687817414.xml · derivative · entry 1 Crane Rosemary A · CIK 0001443343 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2033-06-21 F1 · derivative.exercise_date: Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2023 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. Read SEC document |
| June 22, 2023 Filed Jun 26, 2023 21:58 UTC |
CHAUDHURI BHASKARDirector
|
GrantRestricted Stock Units · Derivative | 3,350 | $0.00 | $0.00 |
DisclosureSEC source: 0001819790-23-000060 · wk-form4_1687816717.xml · derivative · entry 2 CHAUDHURI BHASKAR · CIK 0001458643 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,350 Underlying: Common Stock · 3,350 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock. F3 · derivative.exercise_date: RSUs granted on June 22, 2023, in connection with the Reporting Person's service as a non-employee director as of the Company's 2023 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. F3 · derivative.expiration_date: RSUs granted on June 22, 2023, in connection with the Reporting Person's service as a non-employee director as of the Company's 2023 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. Read SEC document |
| June 22, 2023 Filed Jun 26, 2023 21:58 UTC |
CHAUDHURI BHASKARDirector
|
GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $17.99 | $0.00 |
DisclosureSEC source: 0001819790-23-000060 · wk-form4_1687816717.xml · derivative · entry 1 CHAUDHURI BHASKAR · CIK 0001458643 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2033-06-21 F1 · derivative.exercise_date: Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2023 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.